AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26856694 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient followed by topical corticosteroids (TCS) applied 15 minutes later, twice daily for 2 weeks.
Number of subjects: 46
Study 26856694 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (TCS) followed by emollient applied 15 minutes later, twice daily for 2 weeks.
Number of subjects: 46
Study 25555191 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dose of verteporfin (PDT)
Number of subjects: 131
Study 25555191 — intervention group
Group type: COMPARATOR
Intervention: 30% dose of verteporfin (PDT)
Number of subjects: 131
Study 24004887 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1500 mg Ca/d)
Number of subjects: 525
Study 24004887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study 20186620 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified D(2) radical total gastrectomy with spleen-preserving
Number of subjects: 112
Study 20186620 — intervention group
Group type: COMPARATOR
Intervention: D(2) radical total gastrectomy with splenectomy
Number of subjects: 112
Study 18280877 — intervention group
Group type: EXPERIMENTAL
Intervention: Antepartum and intrapartum predictors for uterine rupture
Number of subjects: 0
Study 15649575 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention group (n=102)
Number of subjects: 458
Study 15649575 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention group (control group, n=356)
Number of subjects: 458
Study 12127125 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (CLC, n = 26)
Number of subjects: 50
Study 12127125 — intervention group
Group type: COMPARATOR
Intervention: Gasless pneumoperitoneum (GLC, n = 24)
Number of subjects: 50
Study 12127125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GLC and CLC)
Number of subjects: 50
Study 10334416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (300 IU/day)
Number of subjects: 40
Study 10334416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10334416 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 40
Study 7503614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (5 mg/day as a starting dose followed by 5 mg at the 24th hour and then 10 mg/day)
Number of subjects: 19394
Study 7503614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lisinopril)
Number of subjects: 19394
Study 7503614 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 19394
Study 7503614 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate
Number of subjects: 19394
Study 7503614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glyceryl trinitrate)
Number of subjects: 19394
Study 1958425 — intervention group
Group type: EXPERIMENTAL
Intervention: Exosurf Neonatal (synthetic surfactant)
Number of subjects: 218
Study 1958425 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 218
Study 7180065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (1.5 g)
Number of subjects: 120
Study 7180065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29698772 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT Intensive Management (PIM) teams
Number of subjects: 0
Study 29698772 — intervention group
Group type: COMPARATOR
Intervention: Usual care through PACT
Number of subjects: 0
Study 24756172 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT) using the AttenFocus program
Number of subjects: 60
Study 24756172 — intervention group
Group type: COMPARATOR
Intervention: Control group with a simple, non-hierarchical version of CCT
Number of subjects: 60
Study 24756172 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 60
Study 26111129 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh) provided 4 times at intervals of 2 weeks.
Number of subjects: 80
Study 26111129 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no OMTh during the 8-week study).
Number of subjects: 80
Study 23577552 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkalinized 2% lidocaine/epinephrine 1:100,000 at pH 7.31
Number of subjects: 20
Study 23577552 — intervention group
Group type: COMPARATOR
Intervention: Non-alkalinized 2% lidocaine/epinephrine 1:100,000 at pH 3.85
Number of subjects: 20
Study 20231651 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-alternative forced choice (6-AFC) test
Number of subjects: 238
Study 20231651 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-alternative forced choice (3-AFC) test
Number of subjects: 238
Study 18377706 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID change group (placebo-treated patients)
Number of subjects: 177
Study 18377706 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched pairs)
Number of subjects: 177
Study 18377706 — intervention group
Group type: EXPERIMENTAL
Intervention: MCID change group
Number of subjects: 177
Study 18377706 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study 16671071 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication (LNF)
Number of subjects: 224
Study 16671071 — intervention group
Group type: COMPARATOR
Intervention: Conventional Nissen fundoplication (CNF)
Number of subjects: 224
Study 12797502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumactant (400 mg) administered in two doses (first dose 8 h before allergen exposure, second dose 30 min before exposure)
Number of subjects: 7
Study 12797502 — intervention group
Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 7
Study 10738706 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone for 2 hours with intermittent exercise
Number of subjects: 9
Study 10738706 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 9
Study 9039270 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus daily iron (SPD)
Number of subjects: 222
Study 9039270 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus weekly iron (SPW)
Number of subjects: 222
Study 9039270 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine only (SP)
Number of subjects: 222
Study 9039270 — intervention group
Group type: COMPARATOR
Intervention: SPW and SP
Number of subjects: 222
Study 9039270 — intervention group
Group type: COMPARATOR
Intervention: SP
Number of subjects: 222
Study 9039270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy
Number of subjects: 222
Study 8466728 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (1.25 mg twice daily)
Number of subjects: 368
Study 8466728 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (250 mg twice daily)
Number of subjects: 368
Study 8466728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 8466728 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368
Study 8466728 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368
Study 8466728 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Captopril (25 mg or 50 mg once daily for non-responders)
Number of subjects: 368
Study 3993534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol, 400 mg once daily
Number of subjects: 33
Study 3993534 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 100 mg once daily
Number of subjects: 33
Study 31661958 — intervention group
Group type: EXPERIMENTAL
Intervention: Kernel ridge regression with a training set of randomly selected 5% structures
Number of subjects: 0
Study 31661958 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptors based on pore geometry barcodes
Number of subjects: 0
Study 29064285 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + OR
Number of subjects: 78
Study 29064285 — intervention group
Group type: EXPERIMENTAL
Intervention: BT + OR + S
Number of subjects: 78
Study 29064285 — intervention group
Group type: COMPARATOR
Intervention: BT
Number of subjects: 78
Study 26859648 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid (GA-35%) peel
Number of subjects: 90
Study 26859648 — intervention group
Group type: EXPERIMENTAL
Intervention: Salicylic-mandelic (SM) acid peel (20% salicylic/10% mandelic acid)
Number of subjects: 90
Study 26859648 — intervention group
Group type: COMPARATOR
Intervention: Phytic combination peels
Number of subjects: 90
Study 25222346 — intervention group
Group type: EXPERIMENTAL
Intervention: Split sleep condition (two 5-h sleeping opportunities in 24 h: 0300 h-0800 h and 1500 h-2000 h)
Number of subjects: 53
Study 25222346 — intervention group
Group type: EXPERIMENTAL
Intervention: Nighttime sleep condition (10-h consolidated nighttime sleep: TIB 2200 h-0800 h)
Number of subjects: 53
Study 25222346 — intervention group
Group type: COMPARATOR
Intervention: Daytime sleep condition (10-h consolidated daytime sleep: TIB 1000 h-2000 h)
Number of subjects: 53
Study 22074766 — intervention group
Group type: EXPERIMENTAL
Intervention: Social smoking motive (characters smoked to facilitate social interaction)
Number of subjects: 358
Study 22074766 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation smoking motive (characters smoked to relax)
Number of subjects: 358
Study 22074766 — intervention group
Group type: COMPARATOR
Intervention: No smoking motive (characters smoked with no apparent motive)
Number of subjects: 358
Study 20731529 — intervention group
Group type: EXPERIMENTAL
Intervention: ATOR 20 mg up-titrated to 80 mg
Number of subjects: 80
Study 20731529 — intervention group
Group type: EXPERIMENTAL
Intervention: ROSU 10 mg up-titrated to 40 mg
Number of subjects: 80
Study 20731529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both statins
Number of subjects: 80
Study 19065859 — intervention group
Group type: EXPERIMENTAL
Intervention: Regions perceived as figures in ambiguous, bipartite, 2-D displays
Number of subjects: 0
Study 19065859 — intervention group
Group type: COMPARATOR
Intervention: Regions perceived as grounds in ambiguous, bipartite, 2-D displays
Number of subjects: 0
Study 19065859 — intervention group
Group type: EXPERIMENTAL
Intervention: Regions perceived as grounds (holes) in nested displays
Number of subjects: 0
Study 19065859 — intervention group
Group type: EXPERIMENTAL
Intervention: Unambiguous 3-D cardboard displays of objects versus holes
Number of subjects: 0
Study 15865114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 64
Study 15865114 — intervention group
Group type: COMPARATOR
Intervention: Observation (watchful waiting)
Number of subjects: 64
Study 15865114 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy and Observation (watchful waiting)
Number of subjects: 64
Study 12544987 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 1690
Study 12544987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1690
Study 10194146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 54
Study 8648539 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise program and 8 weeks of classes on nutrition and smoking
Number of subjects: 1274
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 233
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with oral potassium
Number of subjects: 233
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide with oral potassium and magnesium
Number of subjects: 233
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide and triamterene
Number of subjects: 233
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 233
Study 1735925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 1735925 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 233
Study 3878109 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Number of subjects: 57
Study 3878109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31499386 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR)
Number of subjects: 16
Study 31499386 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Static Stretching (SS)
Number of subjects: 16
Study 31499386 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 29517189 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band resistance training
Number of subjects: 54
Study 29517189 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 54
Study 29517189 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 26472111 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive, arthroscopically assisted, antero-lateral approach for cam resection
Number of subjects: 77
Study 24727483 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended, nontailored treatments (12 weeks of counseling, nicotine replacement, and bupropion)
Number of subjects: 777
Study 20733579 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT997 administered by continuous intravenous infusion over 24 h every 3 weeks
Number of subjects: 31
Study 20733579 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT997 doses of >or=65 mg m(‐2)
Number of subjects: 31
Study 20733579 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose levels of CYT997
Number of subjects: 31
Study 20733579 — intervention group
Group type: EXPERIMENTAL
Intervention: CYT997
Number of subjects: 31
Study 15675980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.5 mg kg(‐1) . h(‐1) administered intravenously)
Number of subjects: 20
Study 15675980 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered intravenously)
Number of subjects: 20
Study 12085003 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg of fluticasone propionate (FP) twice daily for 3 months
Number of subjects: 30
Study 12085003 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 3 months
Number of subjects: 30
Study 12085003 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg of fluticasone propionate (FP)
Number of subjects: 30
Study 12085003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9643616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg)
Number of subjects: 9
Study 9643616 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 9
Study 9643616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 7604628 — intervention group
Group type: EXPERIMENTAL
Intervention: Local mitomycin-C (MTM-C) therapy
Number of subjects: 59
Study 7604628 — intervention group
Group type: COMPARATOR
Intervention: Nd-YAG laser treatment
Number of subjects: 59
Study 2844549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg b.i.d. for one month
Number of subjects: 0
Study 2844549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2844549 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol
Number of subjects: 0
Study 2844549 — intervention group
Group type: EXPERIMENTAL
Intervention: Local salbutamol
Number of subjects: 0
Study 2844549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0
Study 11420579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) plus standard medical therapy for CHF
Number of subjects: 408
Study 11420579 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy for CHF
Number of subjects: 408
Study 11420579 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 408
Study 31447514 — intervention group
Group type: EXPERIMENTAL
Intervention: Good basic knowledge of hypertension
Number of subjects: 385
Study 31447514 — intervention group
Group type: EXPERIMENTAL
Intervention: Good attitude towards hypertension
Number of subjects: 385
Study 31447514 — intervention group
Group type: EXPERIMENTAL
Intervention: Good self-care practice towards hypertension
Number of subjects: 385
Study 30287422 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 2.5 mg
Number of subjects: 1707
Study 30287422 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1707
Study 30287422 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1707
Study 30287422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1707
Study 26945817 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant-pregabalin combination
Number of subjects: 87
Study 26945817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 24029220 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 24029220 — intervention group
Group type: COMPARATOR
Intervention: No intervention (exacerbation-free group)
Number of subjects: 0
Study 22815019 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 22815019 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 60
Study 20620618 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillotomy
Number of subjects: 62
Study 20620618 — intervention group
Group type: COMPARATOR
Intervention: Cold dissection tonsillectomy
Number of subjects: 62
Study 20620618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 62
Study 17268908 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented group (18 patients)
Number of subjects: 27
Study 17268908 — intervention group
Group type: COMPARATOR
Intervention: Stentless group (9 patients)
Number of subjects: 27
Study 15248223 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice weekly, subcutaneous injection)
Number of subjects: 28
Study 15248223 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 28
Study 15248223 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 28
Study 15248223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12472517 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone drops
Number of subjects: 18
Study 12472517 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone nasules
Number of subjects: 18
Study 12472517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study 9638413 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality therapy combining pancreatic resection with neo‐ and adjuvant locoregional targeting immunochemotherapy (Group A)
Number of subjects: 26
Study 9638413 — intervention group
Group type: COMPARATOR
Intervention: Pancreatic surgery only (Group B)
Number of subjects: 26
Study 7734455 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance
Number of subjects: 0
Study 2492234 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide, 1 mg subcutaneously per day, administered from the midluteal phase before IVF treatment
Number of subjects: 26
Study 2492234 — intervention group
Group type: COMPARATOR
Intervention: Prior IVF attempts without GnRHa suppression
Number of subjects: 26
Study 4855496 — intervention group
Group type: EXPERIMENTAL
Intervention: Orotic acid (100 mg/kg/day) orally in 2 daily doses from 1st to 5th day of life
Number of subjects: 50
Study 4855496 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 50
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 32-mm heads
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 36-mm heads
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 32-mm heads from 3 months to 6 years
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly cross-linked polyethylene (E-Poly) with 36-mm heads from 3 months to 6 years
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual proximal wear rate for 32-mm heads
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual proximal wear rate for 36-mm heads
Number of subjects: 40
Study 30227721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone remodelling around the cup
Number of subjects: 40
Study 27943522 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with 40 ml of 0.25% bupivacaine
Number of subjects: 71
Study 27943522 — intervention group
Group type: COMPARATOR
Intervention: Wound infiltration with 40 ml of 0.25% bupivacaine
Number of subjects: 71
Study 27943522 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (TAP and control)
Number of subjects: 71
Study 25378135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous firocoxib (57 mg)
Number of subjects: 6
Study 25378135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paste firocoxib (57 mg)
Number of subjects: 6
Study 25378135 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet firocoxib (57 mg)
Number of subjects: 6
Study 22841520 — intervention group
Group type: EXPERIMENTAL
Intervention: metformin (3 g daily)
Number of subjects: 48
Study 22841520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study 22089303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizone Rapid (hypotonic)
Number of subjects: 11
Study 22089303 — intervention group
Group type: COMPARATOR
Intervention: PowerAde (isotonic)
Number of subjects: 11
Study 22089303 — intervention group
Group type: COMPARATOR
Intervention: Gatorade (hypertonic)
Number of subjects: 11
Study 22089303 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaloric)
Number of subjects: 11